Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NELFCD_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NELFCD_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NELFCD_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NELFCD_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NELFCD_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NELFCD_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NELFCD_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00063683 | Liver | Cirrhotic | transcription elongation from RNA polymerase II promoter | 28/4634 | 69/18723 | 2.70e-03 | 1.58e-02 | 28 |
GO:000635411 | Liver | HCC | DNA-templated transcription, elongation | 64/7958 | 91/18723 | 7.00e-08 | 1.44e-06 | 64 |
GO:000636811 | Liver | HCC | transcription elongation from RNA polymerase II promoter | 50/7958 | 69/18723 | 4.32e-07 | 7.22e-06 | 50 |
GO:0032784 | Liver | HCC | regulation of DNA-templated transcription, elongation | 39/7958 | 53/18723 | 4.34e-06 | 5.53e-05 | 39 |
GO:0034243 | Liver | HCC | regulation of transcription elongation from RNA polymerase II promoter | 25/7958 | 32/18723 | 4.38e-05 | 4.26e-04 | 25 |
GO:0034244 | Liver | HCC | negative regulation of transcription elongation from RNA polymerase II promoter | 12/7958 | 16/18723 | 8.74e-03 | 3.40e-02 | 12 |
GO:0032785 | Liver | HCC | negative regulation of DNA-templated transcription, elongation | 13/7958 | 18/18723 | 1.05e-02 | 3.89e-02 | 13 |
GO:00063547 | Oral cavity | OSCC | DNA-templated transcription, elongation | 63/7305 | 91/18723 | 4.86e-09 | 1.07e-07 | 63 |
GO:00063686 | Oral cavity | OSCC | transcription elongation from RNA polymerase II promoter | 48/7305 | 69/18723 | 2.60e-07 | 4.05e-06 | 48 |
GO:00327843 | Oral cavity | OSCC | regulation of DNA-templated transcription, elongation | 36/7305 | 53/18723 | 1.89e-05 | 1.83e-04 | 36 |
GO:00342434 | Oral cavity | OSCC | regulation of transcription elongation from RNA polymerase II promoter | 24/7305 | 32/18723 | 3.83e-05 | 3.37e-04 | 24 |
GO:00342442 | Oral cavity | OSCC | negative regulation of transcription elongation from RNA polymerase II promoter | 13/7305 | 16/18723 | 7.05e-04 | 3.89e-03 | 13 |
GO:00327852 | Oral cavity | OSCC | negative regulation of DNA-templated transcription, elongation | 14/7305 | 18/18723 | 9.51e-04 | 4.96e-03 | 14 |
GO:000635413 | Oral cavity | LP | DNA-templated transcription, elongation | 39/4623 | 91/18723 | 1.08e-04 | 1.31e-03 | 39 |
GO:000636813 | Oral cavity | LP | transcription elongation from RNA polymerase II promoter | 31/4623 | 69/18723 | 1.92e-04 | 2.11e-03 | 31 |
GO:00327851 | Oral cavity | LP | negative regulation of DNA-templated transcription, elongation | 11/4623 | 18/18723 | 1.11e-03 | 9.13e-03 | 11 |
GO:00342441 | Oral cavity | LP | negative regulation of transcription elongation from RNA polymerase II promoter | 10/4623 | 16/18723 | 1.48e-03 | 1.16e-02 | 10 |
GO:003278411 | Oral cavity | LP | regulation of DNA-templated transcription, elongation | 22/4623 | 53/18723 | 5.20e-03 | 3.19e-02 | 22 |
GO:003424311 | Oral cavity | LP | regulation of transcription elongation from RNA polymerase II promoter | 15/4623 | 32/18723 | 5.23e-03 | 3.19e-02 | 15 |
GO:000635415 | Skin | cSCC | DNA-templated transcription, elongation | 48/4864 | 91/18723 | 4.58e-08 | 1.19e-06 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NELFCD | SNV | Missense_Mutation | novel | c.1357C>G | p.Gln453Glu | p.Q453E | | protein_coding | tolerated(0.95) | possibly_damaging(0.894) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
NELFCD | SNV | Missense_Mutation | | c.517N>A | p.Glu173Lys | p.E173K | | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-B6-A0RV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NELFCD | SNV | Missense_Mutation | novel | c.566N>G | p.Ser189Cys | p.S189C | | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-D8-A73W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
NELFCD | SNV | Missense_Mutation | | c.1577N>A | p.Arg526Gln | p.R526Q | | protein_coding | tolerated(0.09) | benign(0.393) | TCGA-OL-A66N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NELFCD | SNV | Missense_Mutation | novel | c.1241N>T | p.Ser414Phe | p.S414F | | protein_coding | deleterious(0.01) | possibly_damaging(0.567) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NELFCD | SNV | Missense_Mutation | rs147835273 | c.827N>A | p.Arg276His | p.R276H | | protein_coding | tolerated(0.08) | possibly_damaging(0.603) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NELFCD | SNV | Missense_Mutation | novel | c.1619N>A | p.Arg540His | p.R540H | | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NELFCD | SNV | Missense_Mutation | | c.537N>C | p.Leu179Phe | p.L179F | | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
NELFCD | SNV | Missense_Mutation | novel | c.1487N>C | p.Met496Thr | p.M496T | | protein_coding | deleterious(0) | benign(0.249) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NELFCD | SNV | Missense_Mutation | | c.688N>C | p.Glu230Gln | p.E230Q | | protein_coding | tolerated(0.62) | possibly_damaging(0.478) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |